JPMorgan initiates Spyre stock with Overweight on IBD pipeline

Spyre Therapeutics (SYRE) presented its autoimmune disease strategy at the Stifel 2026 Virtual Immunology and Inflammation Forum, focusing on antibody combinations. CEO Cameron Turtle highlighted opportunities in inflammatory bowel disease and hidradenitis suppurativa, while acknowledging limitations in rheumatoid arthritis data. The company's shares have surged 474% over the past year to $91.97, but are considered overvalued.

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

Guggenheim named Spyre Therapeutics (SYRE) its top biotech pick after positive Phase II trial data for SPY003, showing 20% clinical remission in ulcerative colitis. The firm highlights durability as a key advantage. Part B of the study is enrolling, with results expected in 2027. Guggenheim maintains a positive rating despite a recent downgrade from Wolfe Research.

Spyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations SPY003 met its primary endpoint with a statistically significant reduction of 10.0 po

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.